Psoriasis has a major impact on mental health, social activities, and quality of life. In a modified Delphi consensus process, experts aimed to define ‘freedom of disease.’ This consensus was the first time that patients were involved in every step.
The effect of psoriasis on well-being and health-related quality of life is often underestimated and may not be captured with current outcome measures [1]. “Why do we need a Delphi consensus on freedom from disease in psoriasis? Because an individual with psoriasis may have different criteria for judging their treatment success,” specialist nurse in psoriasis and PhD student Ms Elfie Deprez (Ghent University Hospital, Belgium) explained [2,3].
The modified Delphi consensus process entails a systematic progression of repeated rounds of voting. It is an effective process for determining expert group consensus where there is little evidence. There were 2 multidisciplinary groups: a facilitating consensus panel with 15 members consisting of 6 people with psoriasis, 3 nurses, and 6 physicians to drive the consent, and a voting group. More than 70% of the voting group were psoriasis patients (n=129), the remaining 30% were healthcare professionals (HCPs). Ms Deprez presented the preliminary outcomes of the consensus.
After the first meeting, 5 core domains were identified by the consensus panel for further discussion: symptom control, beyond skin, well-being, treatment burden, and quality of care. Subsequent workshops refined these themes and identified 5 domains central to the concept of freedom of disease:
-
- management of clinical symptoms,
- psychosocial elements,
- quality of life and well-being,
- treatment, and
- healthcare team support.
“For patients, it is important to have full access to and understanding of available treatments. Building a long-term relationship with patients seems to be a very high priority for HCPs,” Ms Deprez commented on the results.
HCP and patients were generally very well aligned. HCPs rated psychosocial elements generally higher except for one: “I have hope for my future.” “This is the only one that is underestimated by HCPs,” Ms Deprez said. In addition, HCPs are more likely to rate healthcare team support as a higher priority compared with patients.
“It is really important to give people with psoriasis such an important and loud voice. Our study was the first time that patients were involved in every step and I am sure this will help us to define better treatment targets for our patients in the future,” Ms Deprez concluded.
-
- Abrouk M, et al. J Dermatol Treat. 2017;28:488-91.
- Deprez E. Defining ‘Freedom from disease’ in plaque psoriasis: Preliminary outputs using delphi methodology, involving nurses, physicians, and people with psoriasis. FC08.01, EADV Congress 2021, 29 Sept–2 Oct.
- Gottlieb AB, Armstrong AW. J Rheumatol. 2013:40:1428-33.
Copyright ©2021 Medicom Medical Publishers
Posted on
« Ixekizumab superior to secukinumab in real-world psoriasis study Next Article
Treating psoriasis during pregnancies »
Table of Contents: EADV 2021
Featured articles
Letter from the Editor
Long-term disease control in AD could be in reach with anti-OX40 antibody KHK4083
Late-Breaking News
Targeting OX40 in the treatment of atopic dermatitis meets expectations
Superior EASI scores after switch from dupilumab to upadacitinib
CSU: Novel agent targeting Bruton’s tyrosine kinase leads to disease control
Novel JAK3/TEC blocker leads to maintained re-pigmentation in vitiligo
TYK2 inhibitor deucravacitinib shows impressive long-term response in psoriasis
Tapinarof cream for psoriasis leads to high clearance rates and remittive effect
CSU: Ligelizumab likely safe and effective for adolescents
Long-term disease control in AD could be in reach with anti-OX40 antibody KHK4083
Topical JAK1/JAK2 inhibitor effective in vitiligo
Abrocitinib demonstrates fast itch control and skin clearance in atopic dermatitis
AD patients with stable response fare well with a monthly dose of tralokinumab
Opioid receptor agonist difelikefalin disappoints in AD
Atopic Dermatitis: State of the Art
Upadacitinib beats dupilumab in different body regions
Efficacious 2-year AD control with IL-13 inhibitor tralokinumab
Ruxolitinib cream: a safe treatment for elderly AD patients
Novel and upcoming targeted AD treatment
Psoriasis: What's New?
Existing and upcoming small molecules in psoriasis
Treating psoriasis during pregnancies
A patient-related approach to freedom of disease
Ixekizumab superior to secukinumab in real-world psoriasis study
Nail psoriasis: An important target to be treated
Grand debate: Is psoriasis a systemic or skin-only disease?
Spotlight on Alopecia Areata
JAK1/2: A promising novel treatment target in alopecia areata
Alopecia areata: encouraging response rates with JAK3/TEC inhibition
Related Articles
Topical JAK1/JAK2 inhibitor effective in vitiligo
Efficacious 2-year AD control with IL-13 inhibitor tralokinumab

Existing and upcoming small molecules in psoriasis
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy